American Society of Hirudotherapy

Post-Ablation Stroke Despite NOAC Use: Successful Reperfusion Therapy After Dabigatran Reversal with Incidental Discovery of a Large MCA Aneurysm-A Case Report

Case report published in Neurology international (2025)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Case reportClinical LiteratureSari SM et al. · Neurology international, 2025

Abstract

Background: Catheter ablation is an established rhythm-control strategy for atrial fibrillation (AF), yet peri-procedural embolic stroke may still occur despite uninterrupted NOAC therapy. Case presentation: A 49-year-old woman on dabigatran developed acute ischemic stroke three days after AF ablation, presenting with left hemiparesis and dysarthria. Idarucizumab (5 g) enabled safe intravenous thrombolysis followed by emergency endovascular thrombectomy (EVT), achieving complete recanalization (mTICI 3). Angiography revealed an incidental 7 mm right MCA aneurysm at the occlusion site. Dabigatran was resumed on day 4, and one month later, the aneurysm was successfully treated with stent-assisted coil embolization. She remained asymptomatic at two months. Conclusions: This case illustrates how idarucizumab reversal expands reperfusion options by enabling both IVT and EVT in NOAC-treated patients and highlights the diagnostic role of EVT in revealing underlying vascular pathology, emphasizing the need for individualized post-procedural antithrombotic management.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article

Summary

A 49-year-old woman on dabigatran developed ischemic stroke three days after atrial fibrillation ablation; idarucizumab (5 g) enabled intravenous thrombolysis and thrombectomy with complete recanalization, and an incidental 7 mm MCA aneurysm was later treated by stent-assisted coiling.

Context

This case report describes a 49-year-old woman on dabigatran who developed acute ischemic stroke three days after atrial fibrillation ablation and was successfully treated with intravenous thrombolysis and endovascular thrombectomy following reversal with idarucizumab, achieving complete recanalization. The report illustrates how idarucizumab reversal expands reperfusion options by enabling both intravenous and endovascular interventions. The abstract makes no mention of leeches, hirudin, hirudotherapy, or the leech secretome. The paper is a single case report focused on reversing a pharmaceutical anticoagulant to facilitate stroke reperfusion therapy.

Citation

Reference (Vancouver style)

Sari SM, Chen WT, Lee CH, Huang NH, Thu PW, Teoh LL, et al. Post-Ablation Stroke Despite NOAC Use: Successful Reperfusion Therapy After Dabigatran Reversal with Incidental Discovery of a Large MCA Aneurysm-A Case Report. Neurol Int. 2025;17(12):190. doi:10.3390/neurolint17120190. PMID: 41441209

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.